PDF(Pubmed)
Abstract：
BACKGROUND: As treatment agents for diabetes, liraglutide is a long-acting glucagon-like peptide 1 receptor agonist, and dipeptidyl peptidase 4 (DPP4) inhibitors are widely used because of their safety and tolerability. Regular treatment with liraglutide has been reported to significantly reduce blood glucose levels, but the impact of low-dose (0.3 mg) liraglutide on blood glucose levels immediately after treatment switching from a DPP4 inhibitor remains unknown.
METHODS: We conducted a single-arm, retrospective, observational study in 55 inpatients with type 2 diabetes (T2D) to investigate the changes (Δ) in their blood glucose levels at six time points (6-point) from the day before (day -1) to the day after (day 1) by switching the antidiabetic treatment from a DPP4 inhibitor to liraglutide 0.3 mg (low-dose liraglutide) once daily. We also attempted to identify factors associated with the blood glucose-lowering effects of liraglutide.
RESULTS: The median values of the changes in fasting, preprandial, and postprandial blood glucose levels and the fluctuations in the blood glucose levels expressed as the standard deviation of the 6-point blood glucose levels were significantly lower on day 1 than on day -1 (P < 0.05, P < 0.0001, P < 0.0001, P < 0.01, respectively); there were no cases of severe hypoglycemia. The Δ blood glucose levels were not associated with the baseline serum hemoglobin A1c values or with any markers of the insulin secreting capacity. There were no associations between the previously used blood glucose-lowering drug and the Δ blood glucose levels.
CONCLUSIONS: Switching from a DPP4 inhibitor to low-dose (0.3 mg) liraglutide once daily significantly reduced the blood glucose levels and excursions of the blood glucose levels even from the very day after the treatment switch, with no serious adverse events.
METHODS: We conducted a single-arm, retrospective, observational study in 55 inpatients with type 2 diabetes (T2D) to investigate the changes (Δ) in their blood glucose levels at six time points (6-point) from the day before (day -1) to the day after (day 1) by switching the antidiabetic treatment from a DPP4 inhibitor to liraglutide 0.3 mg (low-dose liraglutide) once daily. We also attempted to identify factors associated with the blood glucose-lowering effects of liraglutide.
RESULTS: The median values of the changes in fasting, preprandial, and postprandial blood glucose levels and the fluctuations in the blood glucose levels expressed as the standard deviation of the 6-point blood glucose levels were significantly lower on day 1 than on day -1 (P < 0.05, P < 0.0001, P < 0.0001, P < 0.01, respectively); there were no cases of severe hypoglycemia. The Δ blood glucose levels were not associated with the baseline serum hemoglobin A1c values or with any markers of the insulin secreting capacity. There were no associations between the previously used blood glucose-lowering drug and the Δ blood glucose levels.
CONCLUSIONS: Switching from a DPP4 inhibitor to low-dose (0.3 mg) liraglutide once daily significantly reduced the blood glucose levels and excursions of the blood glucose levels even from the very day after the treatment switch, with no serious adverse events.
摘要：
背景：作为糖尿病的治疗药物，利拉鲁肽是一种长效胰高血糖素样肽1受体激动剂，和二肽基肽酶4（DPP4）抑制剂由于其安全性和耐受性而被广泛使用。据报道，常规治疗利拉鲁肽可显着降低血糖水平，但低剂量(0.3mg)利拉鲁肽对DPP4抑制剂转用后立即血糖水平的影响尚不清楚.
方法：我们进行了单臂，回顾性,在55例2型糖尿病（T2D）住院患者中进行观察性研究，以研究从前一天（第-1天）到第二天（第1天）的六个时间点（6点）的血糖水平变化（Δ）通过将抗糖尿病治疗从DPP4抑制剂转换为每天一次的利拉鲁肽0.3mg（低剂量利拉鲁肽）。我们还试图确定与利拉鲁肽的降血糖作用相关的因素。
结果：空腹，餐前,餐后血糖水平和以6点血糖水平的标准偏差表示的血糖水平波动在第1天明显低于第-1天（分别为P<0.05，P<0.0001，P<0.0001，P<0.01）；没有发生严重低血糖的病例。Δ血糖水平与基线血清血红蛋白A1c值或胰岛素分泌能力的任何标志物无关。先前使用的降血糖药物与Δ血糖水平之间没有关联。
结论：每天一次从DPP4抑制剂转换为低剂量（0.3mg）利拉鲁肽显着降低了血糖水平和血糖水平的波动，甚至从治疗转换后的第二天开始，无严重不良事件。
方法：我们进行了单臂，回顾性,在55例2型糖尿病（T2D）住院患者中进行观察性研究，以研究从前一天（第-1天）到第二天（第1天）的六个时间点（6点）的血糖水平变化（Δ）通过将抗糖尿病治疗从DPP4抑制剂转换为每天一次的利拉鲁肽0.3mg（低剂量利拉鲁肽）。我们还试图确定与利拉鲁肽的降血糖作用相关的因素。
结果：空腹，餐前,餐后血糖水平和以6点血糖水平的标准偏差表示的血糖水平波动在第1天明显低于第-1天（分别为P<0.05，P<0.0001，P<0.0001，P<0.01）；没有发生严重低血糖的病例。Δ血糖水平与基线血清血红蛋白A1c值或胰岛素分泌能力的任何标志物无关。先前使用的降血糖药物与Δ血糖水平之间没有关联。
结论：每天一次从DPP4抑制剂转换为低剂量（0.3mg）利拉鲁肽显着降低了血糖水平和血糖水平的波动，甚至从治疗转换后的第二天开始，无严重不良事件。
